Related Experiment Video
Updated: May 25, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Real-world Glycemic Outcomes of a Tubeless Automated Insulin Delivery System (Medtrum A8 TouchCare) in Adults With
Michele Roberto Modestino1, Mariarosaria De Luca2, Umberto De Fortuna2
1ASL Salerno, Salerno, Italy.
Objectives:
Automated insulin delivery (AID) systems are recommended as a first-line therapy for type 1 diabetes. The Medtrum A8 TouchCare is a tubeless AID system powered by the APGO algorithm, which modulates basal insulin and delivers automatic correction microboluses. Real-world evidence on this system remains extremely limited. In this study, we aimed to evaluate the efficacy of the Medtrum A8 TouchCare in AID mode in a real-world cohort of adults with type 1 diabetes.
Methods:
We conducted a single-centre, observational retrospective study at Federico II University Hospital, Naples, Italy (January to October 2025). Adults with type 1 diabetes of ≥6 months' duration who were using the Medtrum A8 TouchCare in AID mode were included. Continuous glucose monitoring metrics and clinical parameters were compared at baseline and after 3 months. The primary endpoint was the change in time in range.
Results:
A total of 20 patients were included (mean age: 39±6 years; diabetes duration: 18±6 years). After 3 months, time in range increased by 12.51% (p<0.05); time above range 1 and time above range 2 decreased by 7.2% (p<0.05) and 5.97% (p<0.05), respectively. Glucose monitoring index improved by 0.46% (p<0.05) and glycemia risk index by 13.75 points (p<0.05), and glycated hemoglobin decreased by 0.52% (p<0.05). No significant changes were observed in time below range 1, time below range 2, or coefficient variability, and no severe hypoglycemia episodes occurred.
Conclusions:
The Medtrum A8 TouchCare in AID mode significantly improved glycemic management without increasing hypoglycemia. These findings support the efficacy of this tubeless AID system and warrant confirmation in larger prospective studies.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Hypoglycemia